Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 48

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 48
---
i) 8,918 shares of common stock; and (ii) 877,557 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

Consists of 77,539 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

Consists of 11,111 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

Consists of: (i) 1,200 shares of common stock; and (ii) 127,857 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

Consists of 114,071 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

Consists of 112,227 shares issuable pursuant to stock options exercisable within 60 days of March 31, 2025.

<div align='center'>28</div>

Consists of: (i) 51,390 shares of common stock directly or indirectly held by all current executive officers and directors as a group; and (ii) 2,282,344 shares of common stock issuable pursuant to options exercisable within 60 days of March 31, 2025.

<div align='center'>29</div>

EXECUTIVE OFFICERS The following table sets forth certain information with respect to our executive officers as of April 15, 2025.

| Name             |     | Age |     | Position(s)                                                                         |
| William P. Quinn |     |  54 |     | President, Chief Executive Officer, Chief Financial Officer, Secretary and Director |
| Grant Yonehiro   |     |  61 |     | Chief Operating Officer and Chief Business Officer                                  |

Biographical information with regard to Mr. Quinn is presented under “Proposal No. 1 – Election of Directors” in this Proxy Statement. Grant Yonehiro has served as our Chief Operating Officer since May 2024 and as our Chief Business Officer since November 2016. From February 2016 to November 2016, Mr. Yonehiro served as Interim Chief Commercial Officer at Vium, Inc., a private biotechnology company. From 2013 to January 2016, Mr. Yonehiro served as Chief Business Officer at Berkeley Lights, a public biotechnology company that merged and was acquired by Bruker. From